These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 15297281

  • 1. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
    Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S.
    Ann Rheum Dis; 2005 Mar; 64(3):403-7. PubMed ID: 15297281
    [Abstract] [Full Text] [Related]

  • 2. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
    De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F.
    Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
    [Abstract] [Full Text] [Related]

  • 3. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ, Smeenk RJ, De Jong J, Feldmann M, Maini RN.
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab.
    Elkayam O, Burke M, Vardinon N, Zakut V, Yitzhak RB, Paran D, Levartovsky D, Litinsky I, Caspi D.
    Autoimmunity; 2005 Mar; 38(2):155-60. PubMed ID: 16040336
    [Abstract] [Full Text] [Related]

  • 6. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy.
    Comby E, Tanaff P, Mariotte D, Costentin-Pignol V, Marcelli C, Ballet JJ.
    J Rheumatol; 2006 Jan; 33(1):24-30. PubMed ID: 16395746
    [Abstract] [Full Text] [Related]

  • 7. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment.
    Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C.
    Arthritis Res Ther; 2004 Jan; 6(3):R264-72. PubMed ID: 15142273
    [Abstract] [Full Text] [Related]

  • 8. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
    Visvanathan S, Wagner C, Smolen J, St Clair EW, Hegedus R, Baker D, Keenan G.
    Arthritis Rheum; 2006 Sep; 54(9):2840-4. PubMed ID: 16948115
    [Abstract] [Full Text] [Related]

  • 9. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, van Vollenhoven RF.
    Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
    [Abstract] [Full Text] [Related]

  • 10. Induction of autoantibodies during prolonged treatment with infliximab.
    Louis M, Rauch J, Armstrong M, Fitzcharles MA.
    J Rheumatol; 2003 Dec; 30(12):2557-62. PubMed ID: 14719194
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
    Atzeni F, Sarzi-Puttini P, Dell' Acqua D, de Portu S, Cecchini G, Cruini C, Carrabba M, Meroni PL.
    Arthritis Res Ther; 2006 Dec; 8(1):R3. PubMed ID: 16356192
    [Abstract] [Full Text] [Related]

  • 12. Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis.
    Benucci M, Saviola G, Baiardi P, Cammelli E, Manfredi M.
    Clin Rheumatol; 2008 Jan; 27(1):91-5. PubMed ID: 17929076
    [Abstract] [Full Text] [Related]

  • 13. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.
    Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P.
    Rheumatology (Oxford); 2006 Jan; 45(1):106-11. PubMed ID: 16287919
    [Abstract] [Full Text] [Related]

  • 14. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus.
    Aringer M, Steiner G, Graninger WB, Höfler E, Steiner CW, Smolen JS.
    Arthritis Rheum; 2007 Jan; 56(1):274-9. PubMed ID: 17195231
    [Abstract] [Full Text] [Related]

  • 15. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab.
    Allanore Y, Sellam J, Batteux F, Job Deslandre C, Weill B, Kahan A.
    Clin Exp Rheumatol; 2004 Jan; 22(6):756-8. PubMed ID: 15638051
    [Abstract] [Full Text] [Related]

  • 16. [Clinical experience with TNF-alpha inhibitors in rheumatoid arthritis].
    Wallenius M, Rødevand E, Skomsvoll JF.
    Tidsskr Nor Laegeforen; 2005 Jun 16; 125(12):1664-6. PubMed ID: 15976836
    [Abstract] [Full Text] [Related]

  • 17. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment.
    Paulus HE, Wiesner J, Bulpitt KJ, Patnaik M, Law J, Park GS, Wong WK.
    J Rheumatol; 2002 Dec 16; 29(12):2513-20. PubMed ID: 12465144
    [Abstract] [Full Text] [Related]

  • 18. Antibodies against polyriboadenylic acid in systemic lupus erythematosus and rheumatoid arthritis demonstrated by ELISA. Prevalence of and relation to antibodies against DNA and extractable nuclear antigens.
    Gripenberg M, Piirainen H, Linder E.
    Scand J Rheumatol; 1981 Dec 16; 10(1):33-7. PubMed ID: 6971488
    [Abstract] [Full Text] [Related]

  • 19. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T.
    Arthritis Rheum; 2006 Dec 16; 54(12):3782-9. PubMed ID: 17133559
    [Abstract] [Full Text] [Related]

  • 20. Anti-TNF-alpha-induced systemic lupus syndrome.
    Debandt M, Vittecoq O, Descamps V, Le Loët X, Meyer O.
    Clin Rheumatol; 2003 Feb 16; 22(1):56-61. PubMed ID: 12605321
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.